WO2024044622 - ANTI-DRUG ANTIBODY ASSAYS
National phase entry:
Publication Number
WO/2024/044622
Publication Date
29.02.2024
International Application No.
PCT/US2023/072710
International Filing Date
23.08.2023
Title **
[English]
ANTI-DRUG ANTIBODY ASSAYS
[French]
DOSAGES D'ANTICORPS ANTI-MÉDICAMENT
Applicants **
AMGEN INC.
Inventors
MILLER, Mieke Jill
KING, Chadwick T.
KROENKE, Mark Andrew
STARCEVIC MANNING, Marta
Priority Data
63/373,426
24.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2617 | |
| EPO | Filing, Examination, Granting | 12472 | |
| Japan | Filing, Examination, Granting | 2325 | |
| South Korea | Filing, Examination, Granting | 2371 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,525
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates methods of detecting anti-drug antibodies and kits for using such assays.[French]
La présente invention concerne des méthodes de détection d'anticorps anti-médicament et des kits d'utilisation de tels dosages.